Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.

Proton RahmanChristopher T RitchlinPhilip S HelliwellWolf-Henning BoehnckePhillip J Mease Alice B GottliebShelly KafkaAlexa P KollmeierElizabeth C HsiaXie L XuMay ShawiShihong ShengPrasheen AgarwalBei ZhouParaneedharan RamachandranYanli ZhuangIain B McInnes

Published in: The Journal of rheumatology (2021)

Guselkumab 100 mg Q4W and Q8W were well tolerated in patients with PsA, with no new safety concerns through 1Y of the phase III DISCOVER trials. Guselkumab safety through 1Y in patients with PsA is consistent with that established in patients with psoriasis who were treated with guselkumab. [ClinicalTrials.gov: NCT03162796 and NCT03158285].

Keyphrases

phase iii
open label
clinical trial
prostate cancer
double blind
phase ii
placebo controlled
randomized controlled trial
study protocol